Tag: Research & Development
NIH Awards $50 Million to Top Autism Researchers Despite Political Controversy
The $50 million in grants will examine how genetics and environment interact
Advances in Cancer Research Described in 15th Cancer Progress Report
20 new anticancer therapeutics, two new devices, two minimally invasive tests, AI-based tools for early detection approved by FDA
Evidence Insufficient to Determine Benefits of Multicancer Screening Tests
Sensitivity ranged from 0.095 to 0.998; specificity from 0.657 to 1.0; AUC from 0.52 to 1.0 across tests
GLP-1 Receptor Agonist Use Linked to Reduced Overall Risk for Cancer in Adults With...
Significantly lower risks seen for endometrial cancer, ovarian cancer, meningioma; nonsignificantly increased risk seen for kidney cancer
Nike Co-Founder And Wife Donate $2B to Cancer Research at OHSU, Largest U.S. University...
By I. Edwards HealthDay Reporter
MONDAY, Aug. 18, 2025 (HealthDay News) — Nike co-founder Phil Knight and his wife, Penny, will donate $2 billion to...
RFK Jr. Cancels $500M in mRNA Vaccine Research Projects
By I. Edwards HealthDay Reporter
THURSDAY, Aug. 7, 2025 (HealthDay News) — U.S. Department of Health and Human Services (HHS) Secretary Robert F. Kennedy Jr....
FDA Warns About Safety Issues With Boston Scientific Heart Devices
By I. Edwards HealthDay Reporter
THURSDAY, Aug. 7, 2025 (HealthDay News) — U.S. health officials are warning patients and physicians about safety issues associated with...
Gates Foundation to Spend $2.5 Billion on Women’s Health by 2030
By I. Edwards HealthDay Reporter
WEDNESDAY, Aug. 6, 2025 (HealthDay News) — The Bill & Melinda Gates Foundation announced Monday it will invest $2.5 billion...
U.K. Begins Major Research Effort Into Trans Youth Health
By I. Edwards HealthDay Reporter
TUESDAY, Aug. 5, 2025 (HealthDay News) — A large new study will follow the health and well-being of thousands of...
Many Ineligible for Clinical Trial Could Benefit From Teclistamab for Multiple Myeloma
89 percent of 509 patients would have been ineligible for MajesTEC-1 trial; estimated median PFS was 5.8 months
